Results 241 to 250 of about 363,866 (292)

Lost and Found: Is Olfactory Recovery More Promising After COVID‐19 Than Other Causes, Even 2 Years Later?

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Olfactory dysfunction is a hallmark feature of COVID‐19, yet the potential for recovery with long‐standing COVID‐19‐related smell loss (CRSL) remains uncertain, particularly when treatment is initiated years later. This study evaluated olfactory outcomes in patients with CRSL compared with non‐COVID‐19‐related smell loss (non‐CRSL),
John W. Hunsicker, Mabel Berg, Nicolaus Knight, Jessica W. Grayson, Bradford A. Woodworth, Justin H. Turner, Do‐Yeon Cho   +6 more
wiley   +1 more source

Developmental milestones and cognitive trajectories in school-aged children with 16p11.2 deletion. [PDF]

J Neurodev Disord
Verbesselt J, Breckpot J, Zink I, Swillen A.   +3 more
europepmc   +1 more source

Equine models in translational medicine: A comparative approach to human health

Animal Models and Experimental Medicine, EarlyView.
This diagram summarizes and contrasts rodent and equine models, outlining their strengths, limitations, and applications. Horses offer naturally occurring diseases, genetic and physiological similarities to humans, and suitability for longitudinal and clinical‐scale studies.
Shayan Boozarjomehri Amnieh, Katarzyna Ropka‐Molik   +1 more
wiley   +1 more source

Polygenic risk score of Alzheimer's disease is associated with cognitive trajectories and phenotypes of cerebral organoids. [PDF]

Alzheimers Dement
Chun MY, Jung SH, Choe J, Lee SY, Kim HR, Son HJ, Choi Y, Cho M, Kim B, Jang H, Choi SH, Jeong JH, Son SJ, Hong CH, Roh HW, Na DL, Seo SW, Won HH, Seo J, Kim HJ.   +19 more
europepmc   +1 more source

Cancer therapy‐induced ototoxicity: Current challenges and emerging management strategies

Animal Models and Experimental Medicine, EarlyView.
This review comprehensively examines the key risk factors for cancer therapy‐induced ototoxicity, including cumulative drug dose, genetic susceptibility, and combined treatment regimens. It highlights current challenges in ototoxicity monitoring, such as insufficient timeliness and limited clinical adoption, and advocates for standardized auditory ...
Yuqi Huang, Baoying Xu, Xinru Chen, Yu Chen, Dehong Yu   +4 more
wiley   +1 more source

Temporal Modeling of Amyloid and Tau Trajectories in Alzheimer's Disease Using PET and Plasma Biomarkers

Annals of Neurology, EarlyView.
Objective This study aimed to compare positron emission tomography (PET) and plasma‐based temporal modeling of amyloid and tau biomarkers in Alzheimer's disease. Methods Longitudinal amyloid PET (n = 1,097, mean age ± SD = 72.5 ± 7.38 year, 51.4% male), 18F‐flortaucipir tau‐PET (n = 230, 74.3 ± 7.18 year, 52.2% female), and Fujirebio Lumipulse plasma p‐
Christopher A. Brown, Katheryn A.Q. Cousins, Magdalena Korecka, Emily McGrew, Alice Chen‐Plotkin, John A. Detre, Corey T. McMillan, Edward B. Lee, Sandhitsu R. Das, Dawn Mechanic‐Hamilton, Paul A. Yushkevich, Ilya M. Nasrallah, Leslie M. Shaw, for the Alzheimer's Disease Neuroimaging Initiative, David A. Wolk   +14 more
wiley   +1 more source

Technology Activities and Cognitive Trajectories Among Community-Dwelling Older Adults: National Health and Aging Trends Study. [PDF]

JMIR Aging
Hsu EC, Spaulding EM, Jutkowitz E.
europepmc   +1 more source

Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's disease. [PDF]

Alzheimers Dement
Devanarayan V, Donohue MC, Sperling RA, Johnson KA, Ye Y, Charil A, Doherty T, Tian L, Raman R, Aisen PS, Kramer LD, Irizarry MC, Dhadda S.   +12 more
europepmc   +1 more source